180 Life Sciences (ATNF) Stock Price, News & Analysis

Company Overview

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Key Stats

• Today's Range: $11.67 to $17.46
• 50-Day Range: $0.80 to $10.24
• 52-Week Range: $0.66 to $17.75
• Volume: 70.62 million shs
• Average Volume: 3.06 million shs
• Market Capitalization: $61.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

180 Life Sciences Stock Analysis - MarketRank™

180 Life Sciences scored higher than 19% of companies evaluated by MarketBeat, and ranked 860th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for 180 Life Sciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of 180 Life Sciences is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 180 Life Sciences is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

180 Life Sciences has a P/B Ratio of 12.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.89% of the float of 180 Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

180 Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 180 Life Sciences has recently decreased by 0.31%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

180 Life Sciences does not currently pay a dividend.

Dividend Growth

180 Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.89% of the float of 180 Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

180 Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 180 Life Sciences has recently decreased by 0.31%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.31

News Sentiment

180 Life Sciences has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for 180 Life Sciences this week, compared to 0 articles on an average week.

Search Interest

25 people have searched for ATNF on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added 180 Life Sciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, 180 Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

38.20% of the stock of 180 Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 4.07% of the stock of 180 Life Sciences is held by institutions.

ATNF Stock Analysis - Frequently Asked Questions

How have ATNF shares performed this year?

180 Life Sciences' stock was trading at $1.82 on January 1st, 2025. Since then, ATNF shares have increased by 522.9% and is now trading at $11.3360.

How were 180 Life Sciences' earnings last quarter?

180 Life Sciences Corp. (NASDAQ:ATNF) released its quarterly earnings results on Wednesday, July, 23rd. The company reported ($0.30) EPS for the quarter.

When did 180 Life Sciences' stock split?

180 Life Sciences shares reverse split before market open on Wednesday, February 28th 2024.The 1-19 reverse split was announced on Wednesday, February 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of 180 Life Sciences?

Shares of ATNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 180 Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 180 Life Sciences investors own include Meta Platforms (META), NIO (NIO), Enterprise Products Partners (EPD), HubSpot (HUBS), Netflix (NFLX), Plug Power (PLUG).

Company Calendar

• Last Earnings: 7/23/2025
• Today: 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATNF
• CIK: 1690080
• Web: www.kblmerger.com
• Phone: (650) 507-0669
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($15.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -141.25%
• Return on Assets: -80.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.58
• Quick Ratio: 0.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.89 per share
• Price / Book: 11.51

Miscellaneous

• Outstanding Shares: 6,040,000
• Free Float: 3,732,000
• Market Cap: $61.85 million
• Optionable: No Data
• Beta: 0.38